DEV Community: Yanming Liu

FDA Approves Novo Nordisk Awiqli as First Once Weekly Insulin for Children With Type 2 Diabetes

Yanming Liu — Fri, 23 Oct 2026 20:46:40 +0000

Novo Nordisk won US clearance on October 23, 2026 for Awiqli, or insulin icodec-abae, as a once weekly basal insulin for children aged 10 and older with type 2 diabetes. The Food and Drug Administration approval makes the 700 units/mL injection the first once weekly basal insulin available for pediatric type 2 diabetes in the United States. The product is already familiar to adult patients, but the pediatric label turns seven basal injections a week into one.

Type 2 diabetes in young people is not a small or static problem. Novo Nordisk cited a modeling study projecting nearly 84,000 people aged 19 or younger in the United States with type 2 diabetes by 2050. Eda Cengiz, MD, MHS, professor of pediatrics at the University of California, San Francisco, said in Novo's announcement that children with type 2 diabetes face an aggressive disease trajectory and that daily basal injections have been a mainstay of pediatric care for more than 20 years.

Awiqli is not a new chemical entity for adults. The FDA approved the adult type 2 diabetes indication in March 2026, making it the first once weekly basal insulin for adults with type 2 diabetes, Healio reported. The pediatric approval builds on the adult evidence package and a single dose pharmacokinetic study in patients aged 10 to under 18 with type 2 diabetes. Novo said results from that study plus data from the ONWARDS clinical trials supported the pediatric indication.

The approval lands in a competitive but uneven market. Eli Lilly's insulin efsitora alfa-gobe, sold as Onswik, was approved about one month earlier as the second once weekly basal insulin for adults, according to Healio. Onswik is not currently approved for children, leaving Novo with the only pediatric weekly basal insulin in the US market. Pediatric type 2 diabetes has few treatment options, and the injection burden is one of the practical limits that clinicians and families discuss.

Key Facts

PR Newswire reported on October 23, 2026 that Novo Nordisk announced FDA approval of Awiqli injection 700 units/mL as an adjunct to diet and exercise to improve glycemic control in children aged 10 years and older with type 2 diabetes. The label specifies once weekly subcutaneous injection on the same day each week using the FlexTouch pen. Basal injections fall from seven per week to one, or from about 365 a year to 52, as Medical Daily reported on August 18, 2026.

Healio reported on October 23, 2026 that the pediatric expansion rests on evidence from adult studies and a single dose pharmacokinetic study in children aged 10 to 17 with type 2 diabetes. Novo said efficacy and safety data from the ONWARDS clinical trials supported the approval. The adult approval had arrived in March 2026, when the FDA cleared the product as the first once weekly basal insulin for adults with type 2 diabetes.

Managed Healthcare Executive reported on August 11, 2026 that Awiqli launched in the US with a list price of $99 per package, a single multi-dose FlexTouch pen. Eligible commercially insured or Medicare patients can pay as little as $35 a month through NovoCare savings programs, while uninsured patients pay $55 a month. Patients whose plans use copay accumulator or maximizer arrangements are excluded from the savings cards. Novo said the product would be available at more than 70,000 US pharmacies.

The adult evidence base is the ONWARDS phase 3a program, which enrolled about 2,680 adults with uncontrolled type 2 diabetes across four randomized trials. Managed Healthcare Executive reported on August 11, 2026 that the trials showed non-inferiority to once daily insulin degludec or insulin glargine plus an oral antidiabetic drug on mean change in HbA1c. The pediatric label does not repeat those adult trials in children. Instead, the FDA relied on adequate and well controlled studies in adults plus the single dose pharmacokinetic study in pediatric patients.

The safety profile includes hypoglycemia, serious allergic reactions, injection site reactions, lipodystrophy, itching, rash, swelling of hands and feet, and weight gain. Novo states that it is not known whether Awiqli is safe and effective in children younger than 10. The product is approved in the US, the EU and 18 additional countries. For US pediatric use, the approval is limited to type 2 diabetes, not type 1 diabetes.

Analysis

The approval is best read as a targeted reduction in treatment burden rather than a redefinition of pediatric diabetes care. Awiqli does not replace metformin, lifestyle support or the broader need for glucose control. It changes the delivery schedule for children who already need basal insulin. Reuters reported on April 23, 2026 that treatment options for young patients remain limited, with doctors typically relying on metformin or insulin for pediatric type 2 diabetes. A once weekly basal option fits inside that narrow set of choices, but it does not expand the set by itself.

What this really means is that convenience has become a regulatory and clinical selling point in a field where adherence is not an abstract concern. A child who needs a daily basal injection depends on a family routine, school schedules and caregiver availability. A weekly injection on the same day each week can reduce those handoffs from 365 to 52 a year. The trade-off is not invisible. Medical Daily reported on August 18, 2026 that because a once weekly insulin stays in the body far longer than a daily one, a dosing error takes longer to correct. European regulators required educational materials on avoiding errors and mix ups when switching from a daily long acting insulin, and the US label keeps the same day each week instruction.

The bigger picture here is that Novo is building a pediatric franchise around an adult product with an established manufacturing and pharmacy footprint. Managed Healthcare Executive reported on August 11, 2026 that the adult label was limited to type 2 diabetes after an FDA advisory committee concluded the data were not sufficient to establish a positive benefit risk profile in type 1 diabetes. Medical Daily reported on August 18, 2026 that the FDA issued a complete response letter in 2024 to an earlier application covering both major diabetes types, citing manufacturing questions and concerns about hypoglycemia risk in type 1 diabetes. An advisory panel voted against type 1 use while raising no comparable safety concern for type 2. The pediatric approval extends the type 2 label to a younger age group using adult evidence and a pediatric pharmacokinetic study.

The competitive contrast with Eli Lilly is sharper than a simple first mover story. Healio reported on October 23, 2026 that Onswik was approved about one month before Awiqli's pediatric expansion as the second once weekly basal insulin for adults and is not currently approved for children. Novo therefore has a pediatric label that Lilly does not have, at least for now. But the adult market is already contested, and the pediatric niche is small relative to the adult type 2 population. The approval gives Novo a differentiated claim, not a mass market monopoly.

Why It Matters

The pediatric approval matters because the numbers behind type 2 diabetes are large and the pediatric slice is growing. Managed Healthcare Executive reported on August 11, 2026 that about 40 million Americans have diabetes and roughly 90% to 95% of them have type 2 diabetes, according to the CDC. Medical Daily reported on August 18, 2026 that more than 36 million people in the United States have type 2 diabetes, with about 22% of them, roughly 8 million people, requiring daily insulin injections to control blood glucose, citing figures reported by the Washington Post. Those adult figures do not describe the pediatric population, but they show the scale of the insulin dependent segment that a weekly option is trying to reach.

For families, the practical difference is a year of fewer injections and fewer opportunities for missed doses. For clinicians, the harder part is switching. Medical Daily reported on August 18, 2026 that switching requires converting the total weekly insulin requirement rather than making a simple substitution, and that the first dose may be handled differently from later ones. That is why the label, the pen and the education materials matter as much as the once weekly schedule. A convenience product that is used incorrectly is not convenient.

For Novo, the approval also arrives while the company is pursuing a broader pediatric diabetes strategy. Reuters reported on April 23, 2026 that Novo's oral GLP-1 drug significantly lowered blood sugar in children and adolescents with type 2 diabetes in a late stage trial, testing 132 patients aged 10 to 17 over 26 weeks. Patients taking the drug lowered average blood sugar by 0.83 percentage points more than those given placebo, a difference the company said was statistically significant. Novo said it would seek regulatory approval for its semaglutide pill and expected to file for label expansions for the Ozempic pill and Rybelsus in the US and EU in the second half of 2026.

Next Up

The next test is access. Novo says Awiqli is stocked at more than 70,000 US pharmacies, but formulary placement is decided plan by plan, and the savings card excludes patients whose plans use copay accumulator or maximizer arrangements. Pediatric use will depend on whether clinicians convert weekly insulin requirements correctly and whether families can navigate prior authorization and cost sharing. The label does not answer the question for children younger than 10, and Novo states that safety and effectiveness in that group are not known.

The competitive and clinical agenda is already moving. Healio reported on October 23, 2026 that Onswik is not approved for children, leaving Novo alone in the US pediatric weekly basal insulin market for now. Reuters reported on April 23, 2026 that Novo expected to file for pediatric label expansions for its semaglutide pill products in the US and EU in the second half of 2026. If those filings advance, Novo could end up with both a weekly insulin and an oral GLP-1 option for young patients with type 2 diabetes. The FDA approval of Awiqli is one step in that broader push, not the end of it.

Australia's Federal Court orders Apple to open iOS and restore Fortnite by March 2027

Yanming Liu — Fri, 23 Oct 2026 20:25:06 +0000

The Federal Court of Australia has ordered Apple to dismantle the closed iOS distribution model it has defended for more than a decade, ruling that the company must admit third-party app stores, allow apps to be installed from the open web and permit alternative payment methods for Australian users by noon Australian Eastern time on 1 March 2027. The Law Society Journal reported on October 23 that the 217-page judgment (2026 FCA 1552), delivered by Justice Jonathan Beach on 22 October 2026, found that Apple Inc had engaged in conduct contravening section 46(1) of the Competition and Consumer Act 2010 in the market for app distribution services on iOS and in the market for iOS in-app payment solutions.

The decision closes the remedies phase of a case Epic Games brought in the United States in 2020, challenging Apple's control over transactions inside applications that run on iOS and the restrictions it places on how those apps reach consumers. Reuters reported on October 22 that the dispute has since drawn scrutiny from courts and regulators in a number of markets, including the European Union, the United Kingdom and Australia. The Australian remedies ruling follows a liability judgment in August 2025, in which the same court found that both Apple and Google had misused their market power in the operation of their mobile app stores.

That liability finding described a system built on terms developers could not negotiate. Anyone wanting to distribute software to iOS users had to go through the App Store, sign a licence agreement with non-negotiable terms and comply with App Store Review Guidelines. The guidelines prevented users from reaching content, subscriptions or features bought on a developer's own website or through another distribution channel unless the same items were also offered as in-app purchases inside the App Store. The terms also required developers to appoint Apple Inc and Apple Pty Limited as their agent for the marketing and delivery of their apps to Australian iOS users. Apple's commissions ran between 15 and 30 per cent.

Fortnite has been absent from Australian iPhones for six years, after Epic inserted a direct payment option into the game in defiance of Apple's rules and Apple removed it. The remedies judgment ends that absence. Epic said Fortnite would return to the Australian App Store on 23 October 2026, and chief executive Tim Sweeney described the outcome on X as 'a huge victory for consumers and developers'.

Key Facts

TechRadar reported on October 23 that the orders take effect at noon Australian Eastern time on 1 March 2027, with a possible extension to 3 May if the court approves one, and that Apple has until 15 February 2027 to lodge an appeal. The orders require Apple to take all steps necessary to let Epic Games and any other developer use payment methods other than Apple's own in-app purchase system. They also allow Australian users to download apps directly from developers and from rival app stores, and they bar Apple from charging fees on purchases made through third-party stores.

ABC News reported on October 23 that Justice Beach ordered Apple to pay 85 per cent of Epic Games' legal costs from the months-long trial, in a decision affecting an estimated 15 million Australian Apple users. Capital Brief reported on October 22 that the costs covered by that order could top A$2 million, or roughly US$1.3 million. The timetable is staged: Apple must complete the changes by March 2027, and the court has left room for a short extension into May.

The judgment does not merely state a principle. It names and prohibits the mechanisms Apple has used in other jurisdictions to blunt similar orders: a Core Technology Fee of 50 euro cents per first annual install, a 27 per cent commission on transactions completed through external websites, disclosure sheets, forcing developers into new bundled contracts in order to use alternative distribution, requiring developers to display Apple's In-App Purchase button alongside their preferred payment method, and forcing developers to appoint Apple as their legal agent for marketing and delivery. Justice Beach called such measures 'deterrence tactics' that blocked 'any genuine prospect of competition'.

The reasoning is unusually direct about how the company behaves when it is constrained. 'In response to regulatory or judicial constraints imposed in connection with the App Store that are anything other than detailed, prescriptive and precise, Apple has systematically implemented practices that seek to circumvent the practical effects of those constraints,' the ruling read. Beach also found that Apple 'devised and pursued a deliberate and comprehensive strategy of foreclosure in relation to iOS app distribution', and described the company's conduct towards Epic as 'a paradigm example of its enforcement of the restrictive terms'.

Apple said it disagreed with many of the court's findings. 'We will request a stay and appeal the outcome to seek a resolution that respects our intellectual property and protects the safe, secure experience that consumers and developers expect from the App Store,' an Apple spokesperson told Reuters on October 22. The company also said it 'does not have a monopoly position in Australia or in any market around the world'. During the case Apple cited security and intellectual property concerns in its defence of the existing rules.

Analysis

What this really means is that the argument has moved on from whether Apple's walled garden is lawful to what a court has to write down to make Apple actually open it. Earlier interventions produced broad obligations, and Apple answered them with fee structures, disclosures and contractual requirements that preserved much of its control in practice. Justice Beach's orders read as a direct response to that pattern. They are prescriptive, they are specific, and they name the workarounds in advance, which is the part regulators watching from other capitals will study most closely.

The commercial effect in Australia is smaller than a European Union-wide change because the local market is more compact, but the legal effect travels further. The judgment is a long reasoned decision delivered after a months-long trial, and it rests on findings about conduct rather than on a single jurisdiction's statutory scheme. When a court documents a strategy of circumvention and then drafts remedies around it, other courts and competition authorities have a template to work from, and platform operators have fewer places to hide behind generic compliance language.

Apple's room to manoeuvre is real but narrowing. Its stated plan is to request a stay and appeal, and the appeal deadline of 15 February 2027 sits two weeks before the orders take effect. A stay, if granted, would pause the March timetable while an appeal runs. Yet the ruling gives the company little space to repeat the pattern the court has now documented, because the prohibited list is closed and specific rather than general. Apple's public position, that it holds no monopoly in Australia or anywhere else, is a claim an appeal can test, but it does not answer the section 46 findings about the contracts and technical measures the judge examined.

The case also leaves a second front open. A parallel class action brought by Australian developers will proceed once the present proceedings conclude, and Joel Phibbs, a principal at Phi Finney McDonald, one of the law firms representing those developers, called the ruling 'a win for Australian app developers and consumers who will continue to pursue claims for compensation in the stage 2 proceeding'. Epic, for its part, settled its case against Google in March. Of the Australian orders, Epic said: 'This is great news for developers worldwide and iOS users in Australia who will benefit from an open mobile app ecosystem.'

Why It Matters

The immediate stakes are practical for roughly 15 million Australian Apple users, who will be able to install software from the open web and from stores other than Apple's own from March 2027. For developers, the change attacks the economics at the centre of the case: commissions of 15 to 30 per cent on digital transactions, and rules that pushed payments through Apple's system. The court also ordered Apple to pay 85 per cent of Epic's liability-trial costs, a figure that could exceed A$2 million, which puts a visible price on contested enforcement for a company that has rarely faced one.

The harder question is what counts as compliance. The finding that Apple systematically circumvented constraints that were not detailed, prescriptive and precise will be read closely in the European Union, the United Kingdom and Australia, the markets Reuters identified as having scrutinised the dispute. It suggests that broad principles invite workarounds, and that specificity is the difference between a remedy and a press release. For platform operators, the lesson is that drafting fees and disclosure forms to preserve an old position can become evidence in the next round of litigation.

There is a wider point about app store competition in Australia specifically. The August 2025 liability ruling covered both Apple and Google, and Epic's settlement with Google in March removed one defendant from the remedies fight. With Apple's orders in place, the Australian market becomes a test of whether rival stores and direct downloads actually attract users once the legal barriers fall, and whether the fees the court barred reappear in another form.

Next Up

Attention now turns to the appeal window. Apple has until 15 February 2027 to challenge the orders, and it has said it will seek a stay. If a stay is granted, the noon deadline on 1 March 2027 slips and the Australian changes wait on appellate argument. If it is not, Apple must have third-party distribution, sideloading and alternative payments running within roughly four months of the judgment. The court has also allowed for an extension to 3 May if it approves one.

Fortnite, meanwhile, is already back. Epic said the game would return to the Australian App Store on 23 October 2026, ending a six-year absence that began when the company routed payments around Apple's system. The stage 2 class action is next in line once the Epic proceedings close, with compensation claims from Australian developers still to be heard.

Italy puts AI Act decree into force with cyber agency fines and algorithm dismissal ban

Yanming Liu — Fri, 23 Oct 2026 20:25:05 +0000

Legislative Decree 179/2026 entered into force in Italy on October 23, 2026, after adoption on October 7 and publication in Gazzetta Ufficiale No. 234 on October 8. It is Italy's second implementing measure for Regulation (EU) 2024/1689, the EU AI Act, following Legislative Decree 160/2026 on law enforcement activities and liability. The decree has 54 articles and covers national governance, market surveillance, sanctions, regulatory sandboxes, education, trade secrets and employment law. Its purpose is to turn the EU rulebook into an operating system for Italian authorities.

The legal basis is Article 24 of Law No. 132 of September 23, 2025, Italy's national AI law. The decree keeps the Coordination Committee at the Presidency of the Council of Ministers as the central policy forum. It designates AgID as the national notifying authority for conformity assessment bodies. It makes ACN the market surveillance authority for AI systems. For high risk AI in credit, banking, investment and insurance, it assigns duties to the Bank of Italy, CONSOB and IVASS. The Italian Data Protection Authority is designated for Article 74(8) of the AI Act. This distributed model gives each regulator the part of the AI economy closest to its existing expertise.

Article 41 is the employment core. Final decisions on establishing, modifying or terminating an employment relationship, including disciplinary measures and performance evaluations, cannot be adopted solely on automated processing. The definitive decision must be reserved to a natural person exercising effective and autonomous power. Worker consent is not an exception. A dismissal issued in breach is null and void, and other decisions taken in breach are also null. Workers may request an intelligible explanation of the decision, including the influence of AI and the main parameters considered.

Key Facts

Il Sole 24 Ore reported on October 22, 2026 that the decree sets four tiers of AI Act fines. The highest is up to €35,000,000 or 7% of total annual worldwide turnover for prohibited practices. The next is up to €15,000,000 or 3% for failure to comply with operators' obligations and transparency requirements. A third tier reaches €7,500,000 or 1% for supplying incorrect, incomplete or misleading information. The fourth is up to €1,000,000 or 0.5% for breaches of Articles 27 and 86, covering fundamental rights impact assessment and the right to explanation. For undertakings the maximum is the higher of the fixed amount and the percentage, with the less onerous amount for SMEs, micro enterprises and innovative start ups. For low severity breaches, an order to remedy may replace a fine.

LEXIA reported on October 23, 2026 that Article 4 designates AgID as the national notifying authority for conformity assessment bodies and Article 5 identifies ACN as a market surveillance authority, alongside the Bank of Italy, CONSOB and IVASS for high risk AI in credit, banking, investment and insurance, and the Data Protection Authority for Article 74(8). The Coordination Committee at the Presidency of the Council of Ministers remains the central policy forum. A coordination committee is also planned to share information and facilitate checks with the Guardia di Finanza, Carabinieri, Police and DIA, according to Il Sole 24 Ore. The decree also encourages cross border collaboration with the Regions and in sectors such as defence, justice and fintech.

PwC Italia Blog reported on October 22, 2026 that Article 41 allows AI to support human resources work but not to replace the human decision maker. The final decision must be made by a natural person who independently assesses the algorithm's output rather than simply accepting it. The provision covers performance assessments, assignment of duties, career progression, disciplinary measures and termination. Automated systems may still source and shortlist candidates, even where they exclude applications from later stages. The decree also requires employers to include the effects of AI systems on work organisation, production pace and task allocation in the risk assessment document required under Legislative Decree No. 81/2008, and to provide information and training on associated risks and preventive measures.

Gazzetta Ufficiale reported on October 8, 2026 that the official text confirms candidate search and selection activities are not among the final decisions on establishing the employment relationship, even where they result in exclusion from later stages of selection. Il Fatto Quotidiano reported on October 23, 2026 that Guido Scorza, an Italian data protection lawyer, called this carve out a huge error of assessment and perspective that threatens to deprive millions of qualified people of jobs because of bias in the algorithms and models behind candidate pre screening services. Scorza cited Amazon's abandonment of an early algorithmic recruiting project in 2015 after it showed an extraordinary preference for men over women. He also cited the Harvard Business School and Accenture study Hidden Workers: Untapped Talent, published in 2021 and based on 2,275 executives and 8,720 workers in the United States, the United Kingdom and Germany. According to that study, more than 90% of employers use screening software for first stage candidate selection, 88% admit that qualified workers are rejected because they do not match the job advert exactly, and 48% exclude resumes with work gaps longer than six months.

Analysis

What this really means is that Italy has created a two tier system of accountability. For final employment decisions, the law draws a hard line: a human being with effective and autonomous power must decide, and a dismissal produced solely by an automated system is void. For earlier stages, such as sourcing and shortlisting, the law leaves room for automated exclusion. That distinction allocates legal risk. Employers can automate the top of the hiring funnel while reserving human judgment for the formal act of hiring, promoting or dismissing. Scorza's criticism goes to the heart of this design: if an algorithm removes a candidate from the pipeline, the later human decision may never happen, so protection arrives too late for the person who was screened out.

The bigger picture here is that enforcement capacity will determine whether the decree changes behavior. Italy has not created a single AI regulator with a blank check. It has given ACN the market surveillance role and AgID the conformity assessment notification role, while the Bank of Italy, CONSOB, IVASS and the Data Protection Authority keep sector specific mandates. This matches the EU AI Act's structure, but it also creates coordination costs. A company deploying high risk AI in lending may face several financial regulators, and a data protection question may pull in the Data Protection Authority. The planned coordination committee with the Guardia di Finanza, Carabinieri, Police and DIA is meant to reduce fragmentation. The test will be whether information moves quickly enough to produce timely checks.

The fine structure is severe on paper. Up to €35 million or 7% of worldwide turnover for prohibited practices gives ACN leverage in negotiations and investigations. The lower tiers matter too, because they cover failures of transparency and the supply of incorrect, incomplete or misleading information. Those are the everyday compliance risks for companies that use AI but do not fall into the prohibited category. The concession for SMEs, micro enterprises and innovative start ups, and the possibility of an order to remedy for low severity breaches, suggest that the Italian legislator wants compliance rather than indiscriminate punishment. The open question is resources. Fines are not self executing.

Why It Matters

The decree matters first for workers. Article 41 gives Italian employees a direct legal ground to challenge dismissals and other adverse decisions taken solely by automated systems. The remedy is not a small procedural fix: the dismissal is null and void. The worker can also ask for an intelligible explanation of the decision, including the main parameters considered and the influence of AI. That explanation right will force employers to document how algorithms feed into human resources decisions. It will also test whether human oversight is real or a rubber stamp. A manager who simply clicks approve on an algorithm's recommendation may not satisfy the requirement of effective and autonomous power.

It matters for companies because the compliance map is now more concrete. ACN is the market surveillance authority, AgID is the notifying authority for conformity assessment bodies, and the Bank of Italy, CONSOB and IVASS supervise high risk AI in credit, banking, investment and insurance. The Data Protection Authority handles its designated AI Act provision. Companies must map which authority governs which system and how they will document human intervention in employment decisions. The four tiers of fines, from €35 million or 7% down to €1 million or 0.5%, create a ladder of risk, and the reputational effect of an ACN investigation may exceed the monetary penalty. The national regulatory sandbox in Articles 26 to 31 adds a constructive route for businesses, start ups and developers, with priority access for SMEs and start ups. The education chapter receives €100 million from the PN Scuola e Competenze 2021-2027 programme, the only part funded with ad hoc resources.

Next Up

Next up is implementation and legal testing. AgID and ACN must establish the joint task force by joint decree and set up the sandbox's operating rules. The coordination committee must begin sharing information with the Guardia di Finanza, Carabinieri, Police and DIA. Employers must update their risk assessment documents under Legislative Decree No. 81/2008 and review human resources technology contracts for automated screening, performance scoring and termination workflows. The first legal tests are likely to come from dismissal cases and from workers requesting explanations of AI assisted decisions. Scorza's critique has given opponents of the candidate screening carve out a clear argument: the law protects the final human decision but not the automated exclusion that prevents a person from ever reaching it. If ACN enforcement or early court cases show discriminatory outcomes, pressure to close the gap may grow.

Russian Satellite Kosmos 2612 Stalks ICEYE-X36 to Within 500 Metres in Low Earth Orbit

Yanming Liu — Thu, 22 Oct 2026 16:58:42 +0000

Satellite trackers spent the third week of October 2026 watching two objects converge over the Southern Hemisphere, and the gap between them kept shrinking. Kosmos 2612, a Russian military spacecraft launched in April 2026 with almost no public disclosure, maneuvered to within a few hundred metres of ICEYE-X36, a US-registered commercial synthetic aperture radar satellite owned by ICEYE US, the American arm of Finland's ICEYE.

The approach unfolded between October 15 and October 19, and by Monday October 19 the Russian craft had begun to move away. Close passes between spacecraft are not new. What makes this one notable is the combination of circumstances: the target is a private Earth-observing satellite rather than a classified government payload, its operator supplies imagery to Ukraine, and the maneuvering spacecraft belongs to the Russian military.

ICEYE builds small radar satellites that image the ground through cloud and at night. The company is headquartered in Finland, but ICEYE-X36 belongs to its US subsidiary, and at least some ICEYE spacecraft supply imagery to Ukraine under a contract signed in January 2026. That connection to a war already underway in Europe is central to how analysts have read the episode.

Rendezvous and proximity operations require a spacecraft to match another object's orbital plane and velocity. In low Earth orbit that is expensive, because plane changes burn large amounts of propellant. A satellite that has already done that work can then move quickly into close formation with relatively little extra fuel, which is exactly what made the pass worth studying.

Key Facts

LeoLabs, the orbital intelligence company whose radars track objects as small as 2 centimetres, described the event in blunt terms. Ars Technica reported on October 19, 2026 that LeoLabs said Kosmos 2612 'conducted a deliberate series of maneuvers toward ICEYE-X36,' closing from hundreds of kilometres away to extreme proximity, maneuvering around the satellite, remaining nearby for an extended period and then beginning to move away. Adam Marsh, LeoLabs' vice president of technical solutions, put the closest approach at within 500 metres (1,640 feet) and said the two were 'likely quite a bit closer than that.'

The tracking numbers sketch a fast, deliberate approach. Between Thursday October 15 and Friday October 16, Kosmos 2612 closed from more than 320 kilometres to about 4.8 kilometres, LeoLabs told Axios, as Al Jazeera reported on October 20, 2026. Over the weekend the Russian craft moved between positions ahead of and behind the ICEYE satellite, at times within roughly 500 metres, with some independent trackers and reports putting the separation under 30 metres. By Monday October 19 it was moving away at a relative velocity of about 10 mph (17 km/h).

The history matters as much as the geometry. Russia launched six satellites, Kosmos 2609 through Kosmos 2614, in April 2026, with Kosmos 2612 riding a Soyuz rocket from northern Russia. CSIS reported on October 15, 2026 that five of the six executed high-energy maneuvers a month later that raised their inclinations to match the orbital plane of the ICEYE satellite, and that Cosmos 2609 passed within 2.5 kilometres of it on May 26, 2026. None stayed plane matched, so the orbits slowly diverged. Then, over two weeks beginning September 30, 2026, Kosmos 2612 executed a series of burns that brought it back into coplanar alignment and nearly the same altitude.

Nothing in that sequence looked routine to the firms watching. LeoLabs called it 'a controlled approach, changes in relative position, close-proximity loitering, additional small maneuvers, and a controlled departure,' and stated that it was 'not a routine conjunction or fly by.' Jonathan McDowell wrote on X that to his knowledge this is the first low Earth orbit rendezvous of two active satellites where one owner did not give approval. Marco Langbroek of TU Delft, who publicized the pass, called it 'a worrisome cat-and-mouse game' in orbit, and Space.com reported on October 21, 2026 that the two spacecraft may at one point have been separated by just a few metres.

Russia has approached Western satellites before, but not a commercial one at this range. Victoria Samson, chief director of space security and stability at the Secure World Foundation, told Space.com that Kosmos 2543 came within about 30 kilometres of USA 245 in January 2020, and that Kosmos 2558 came within about 70 kilometres of USA 326 in August 2022. Both of those were classified National Reconnaissance Office spacecraft. ICEYE-X36 launched in 2024, and ICEYE operates about 80 such satellites in low Earth orbit, with four more due on a SpaceX rideshare that same week. Neither Roscosmos, ICEYE, the US Space Force nor Russian defense officials offered a substantive public explanation in the days after the pass.

Analysis

The first thing to establish is what the maneuver does and does not prove. A close approach is not an attack. Samson noted that such a maneuver is not inherently aggressive, while arguing that context changes the reading, since Russia and Ukraine are literally at war with each other and that tints any interpretation of Russian activity near a satellite feeding Ukrainian intelligence. The propellant cost of the pass, after months of plane matching, is high enough that the encounter was plainly intentional.

The second is that the menu of possible motives remains open. Samson listed several: Russia may be studying ICEYE's radar capabilities up close, attempting to jam or intercept its communications, or simply demonstrating military prowess in a manner that the Ukrainians cannot respond to. Juliana Suess of SWP Berlin told Al Jazeera that a gap under 5 kilometres is essentially a hop and a skip in space, close enough to enable data interception or jamming, though a kinetic attack is possible and less likely. Mark Hilborne of King's College London stressed the consent problem, calling it the first time a country has done such a maneuver against a commercial satellite without any consent. ICEYE chief executive Rafal Modrzewski told Reuters, as Al Jazeera reported on October 20, 2026, that the company moved its own satellite, which appeared to prompt further Russian maneuvering.

The bigger picture here is that low Earth orbit now has an observable social dimension no treaty text anticipated: commercial satellites are infrastructure for militaries, and they are identifiable, trackable and reachable by anyone with enough propellant. That cuts both ways. Samson's observation that you cannot keep the existence of satellites classified because people can see them is a warning as much as a comfort, since the same public tracking data that let analysts document this pass in near real time also lets a state plan one. She also noted that neither China nor the United States is known to have conducted an uncooperative rendezvous in low Earth orbit, which leaves Russia holding a specific and now repeated practice.

What this really means is that the ambiguity is the strategy. Every reading of the encounter, from capability inspection to signals interception to a bare demonstration, is plausible enough to preserve deniability, while the operational effect is to force a commercial operator to spend propellant and attention on evasion. A satellite forced to burn fuel to escape shortens its mission. That is a cost imposed without a shot fired, and it lands on a private company rather than on a military budget.

Why It Matters

The pass tests a norm that was never written down. No treaty provision says a state may not park a spacecraft 500 metres from another operator's satellite, and there is no enforcement mechanism if it does. What has existed is a custom of restraint. The CSIS commentary by Clayton Swope and Chantal Li published on October 15, 2026 argues that the West needs a unified approach to deter Russia from maneuvering into plane matched orbits near non-Russian satellites, and should decide in advance how it would respond to a hostile act in space. Deciding in advance is the hard part, because the same maneuver can be servicing, inspection or a precursor to a weapon.

The commercial dimension raises the stakes beyond any single spacecraft. ICEYE US said its constellation architecture is designed for continuity and resilience, a statement that implicitly acknowledges losing or displacing one satellite is now a scenario worth planning for. Retired Lt. Gen. John Shaw, quoted by Ars Technica, called the maneuver clear messaging that Russia will conduct aggressive activity near commercial assets. With about 80 ICEYE satellites in orbit and more launching on rideshares, the question is whether resilience means redundancy in numbers or a change in how operators maneuver when a stranger arrives.

A legal thread could tighten as well. In October 2022 a senior Russian foreign ministry official told the United Nations that quasi-civilian infrastructure may be a legitimate target for a retaliatory strike. That statement, paired with an actual close approach to a commercially operated radar satellite serving a country at war, gives Western governments a concrete example to cite when arguing that commercial space assets need protection and that operators need clearer rules of behavior.

Next Up

The immediate question is where Kosmos 2612 goes next. As of Monday October 19 it was drifting away at about 10 mph relative velocity, but the spacecraft has already shown it can return to a coplanar orbit after months of separation, so a second approach cannot be ruled out. Trackers will watch whether other members of the Kosmos 2609 to 2614 group resume maneuvering, and whether ICEYE's four new satellites on the SpaceX rideshare become objects of interest. Both spacecraft travel at roughly 17,000 mph (27,000 km/h), so any future encounter will be measured in metres and seconds.

The policy side will move more slowly, but with more consequence. Watch for public statements from the US Space Force, which had already called out earlier Kosmos maneuvers around ICEYE-X36, and for any coordinated Western response weighing the CSIS recommendation to set red lines in advance. The precedent set between October 15 and October 19 is that an unconsented rendezvous in low Earth orbit is possible, observable and, so far, unpunished.

EA closes BioWare after 31 years and cancels the next Mass Effect

Yanming Liu — Thu, 22 Oct 2026 16:58:41 +0000

BioWare was founded in 1995 in Edmonton, Alberta, and grew into one of the most influential role-playing game studios in the world. Its first big success came in 1998 with Baldur's Gate, built on Dungeons and Dragons rules, and it went on to make Neverwinter Nights, Star Wars: Knights of the Old Republic, the Mass Effect trilogy and several Dragon Age games. Electronic Arts bought the studio in 2007 and kept it at the centre of its narrative ambitions for nearly two decades.

That run ended on 21 October 2026. Electronic Arts told staff that it was closing BioWare, shutting the studio's Edmonton workspace, ending early development on the next Mass Effect game and cutting roughly 400 jobs across the company. BioWare confirmed the news in a post on its official blog the same day, writing: "Now, after more than three decades of shared adventures, BioWare is closing and early development on the next Mass Effect project is ending." The post added that "there is nothing easy about writing those words."

The closure arrives less than three months after EA completed a $55 billion sale to an investor group led by Saudi Arabia's Public Investment Fund, Silver Lake and Affinity Partners, a transaction that closed in August 2026 and left the publisher carrying about $20 billion of debt. It is the company's first major restructuring since it stopped trading publicly.

For a generation of players, the timing is bitter. Mass Effect is widely credited with expanding what big-budget games could do with branching narrative and with its inclusion of same-sex relationships. The studio's final decade, however, was defined by a pivot away from that strength: a multiplayer shooter in 2019 and a sequel in 2024 that did not land.

Key Facts

The changes were laid out in a memo to employees titled "Building EA's Next Chapter," signed by Cam Weber, president and chief studios officer, and David Tinson, president and COO. Variety reported on 21 October 2026 that the memo frames the cuts as a response to a fast-changing industry, quoting the pair: "Over the past several months, we've taken a hard look at our business, how we operate, and what it will take to lead in this next era of interactive entertainment." On BioWare, the memo said: "BioWare is a legendary studio that helped define the role-playing genre, and we do not take this decision lightly."

EA last reported 14,500 employees, so the roughly 3% reduction works out to around 400 staffers. The Verge reported on 21 October 2026 that Bloomberg put the total at around 400, including about 50 at BioWare. The Associated Press reported on 22 October 2026, in a story published by The Globe and Mail, that the cancelled Mass Effect would have been the fifth game in the series since 2007.

BBC Newsbeat reported on 22 October 2026 that BioWare closes after 31 years and that its last two releases did not meet sales expectations. The studio built its name on single-player role-playing games, then pivoted to multiplayer with Anthem in 2019, which disappointed fans and critics, before releasing Dragon Age: The Veilguard in 2024, which drew lukewarm reviews, particularly from long-time fans who complained it lacked the complex moral choices of its predecessors. EA had already laid off BioWare staff in 2025 after The Veilguard missed sales expectations.

Elsewhere in the portfolio, the memo says EA will bring Respawn Entertainment and DICE together to collaborate on a future project. Variety reported on 21 October 2026 that multiple sources confirmed the project is Star Wars: Battlefront 3 for Lucasfilm. EA said it will invest heavily in Apex Legends over the next few years with new multiplayer modes, and that it remains committed to Marvel's Iron Man and the next Star Wars Jedi game while concentrating on "fewer simultaneous, large-scale projects."

At EA Sports, the company says two unannounced projects are in development: a social-first open-world American football game code-named Project Gridiron and a Fight Night revival in pre-production, the first in that series after a 15-year hiatus. In the lifestyle group, EA will prioritise Project Evergreen for The Sims, pause Project Lotus and shrink the skate. team. Battlefield 6 was described in the memo as "a great success."

Analysis

Read the memo closely and the logic is not really about Mass Effect at all. EA says it will focus on "fewer simultaneous, large-scale projects," which is the language of a company managing a balance sheet rather than a creative slate. A $55 billion buyout financed partly with about $20 billion of debt creates a very specific kind of pressure: every studio has to justify its next three years in advance, and a role-playing game in early development, years away from revenue, is the easiest line to cut.

What this really means is that BioWare was not closed for making bad games. It was closed because its best work no longer fits the shape of the business EA needs to run. Single-player narrative role-playing games carry long timelines, high variability and no recurring revenue, while the memo's growth language points firmly at shooters, sports and live services. Anthem was the studio's attempt to cross that divide, and it failed on both sides: it alienated the single-player audience and did not find the loyal online audience that sustains Fortnite or Overwatch.

The bigger picture here is consolidation. The Verge reported on 21 October 2026 that Mass Effect: Andromeda in 2017 was widely seen as a misstep, that Anthem did not pan out and that EA cut BioWare staff in 2025 after The Veilguard missed expectations. That is four disappointments in nine years by the standards of a publisher that measures everything against tentpole returns, and private ownership removed whatever patience public markets had once imposed.

There is an irony worth naming. BioWare's own farewell message lists its franchises in chronological order, from Baldur's Gate through Anthem, as if to insist the studio be remembered for the whole arc rather than the last two entries. It is a fair claim, but it is also a claim that no longer has a company behind it.

Why It Matters

BioWare's influence runs well beyond its own sales. Mass Effect is regarded as having a lasting effect on the industry for its ambitious narrative and its inclusion of same-sex relationships, and the studio's choice-driven design shaped how a generation of developers thought about player agency. The closure removes one of the few large studios still identified with that tradition inside a major publisher.

It also matters geographically and economically. The Edmonton workspace is being shut and roughly 400 people are losing their jobs across EA, about 50 of them at BioWare. The reaction from peers was immediate: Michal Nowakowski, co-CEO of CD Projekt Red, said BioWare had been "a massive part" of the Polish studio's history and wrote: "Not a great day in the games industry."

The people who voiced the games responded too. Jennifer Hale and Mark Meer, who played the female and male versions of Commander Shepard, spoke on an Instagram livestream, where Hale said "BioWare lives on. Mass Effect lives on. We live on," and the pair closed with Shepard's line, "I should go."

Next Up

The immediate question is what survives. EA says it is continuing with Marvel's Iron Man and the next Star Wars Jedi game, and the Respawn and DICE collaboration on Star Wars: Battlefront 3 is the company's clearest statement of where its shooter investment is going. On the sports side, Project Gridiron and the Fight Night revival will be watched as tests of whether EA Sports can carry the portfolio while the rest of the business narrows.

Beyond EA, attention turns to the Amazon Mass Effect television series, which IGN later reported remains in development despite the game cancellation, and to whether the roughly 400 people affected find new roles in a contracting market. For now, the studio that spent 31 years asking players to make impossible choices has had one made for it.

Nigeria Confirms First Imported Bundibugyo Ebola Case as Outbreak Reaches West Africa

Yanming Liu — Thu, 22 Oct 2026 16:39:10 +0000

Nigeria's Federal Ministry of Health and Social Welfare confirmed on October 20, 2026, one imported case of Ebola Bundibugyo virus disease in the Federal Capital Territory, making Nigeria the fifth country to detect the virus in an outbreak declared in the Democratic Republic of the Congo on May 15, 2026. The patient is a woman who flew to Abuja from Uganda on October 3, according to the WHO Regional Office for Africa, and her symptoms began on October 7, four days after her arrival in Nigeria.

The WHO Regional Office for Africa reported on October 20 that the case was laboratory confirmed as Bundibugyo virus and that the patient was in isolation and receiving medical care. The agency said 44 contacts had been identified and were being monitored, and that infection prevention and control measures were being ramped up at the private health facility in Abuja where she sought care on October 11.

The detection takes the DRC-born outbreak into West Africa for the first time in the current response. Al Jazeera reported on October 21 that Nigerian officials said the case matches the Bundibugyo strain behind the DRC outbreak and that the Nigeria Centre for Disease Control and Prevention confirmed it after three molecular tests. WHO says Nigeria is the fifth country to detect the virus in this outbreak, which has also widened in East Africa, where Kenya has reported nine cases linked to an imported case in recent weeks.

Bundibugyo is a relatively rare Ebola virus species with no approved vaccine or specific treatment, although trials are under way. Ebola's incubation period is two to 21 days. Nigeria's last experience with the disease, in 2014, was different in important ways: the first case in Lagos was contained within three months, resulting in 20 infections and eight deaths, while the West African epidemic killed more than 11,000 people between late 2013 and 2016, according to Al Jazeera.

Key Facts

BBC News reported on October 21 that the patient is the Ugandan-born wife of a diplomat who is based in Abuja. She is 42 years old, spent two and a half weeks in Kampala and made a two-hour stopover in Addis Ababa, Ethiopia, on her return, according to Health Minister Muhammad Ali Pate. Pate told the BBC that she was stable and improving. The woman arrived home on October 3, and the case was confirmed on Tuesday, October 20, after three laboratory tests.

The Nigeria Centre for Disease Control and Prevention tested the woman for Ebola on October 19 after officials learned she had recently travelled to Uganda, and the positive result was confirmed the next day. Olajumoke Babatunde, director of the public health laboratory service at NCDC, said the agency did three levels of tests, all molecular, and that the strain was Bundibugyo. WHO also confirmed the strain. The patient first went to a private hospital thinking she had malaria, then to a second private hospital, and was admitted on October 11, according to BBC News. Public health authorities were alerted on October 19 after her condition failed to improve.

Authorities identified 44 contacts, most of them healthcare workers, including the patient's husband, a Swiss national living with her in Abuja. Pate said not all the contacts were in close proximity and that officials cast the net wide. Aviation Minister Festus Keyamo said 46 people, the 44 who came into contact with the woman at hospital and two who worked in her home, were banned from boarding flights. Nigeria stepped up Ebola surveillance at international airports with health screenings, temperature checks, movement tracking and digital health declarations, and neighbouring Cameroon tightened airport and port surveillance. No contacts are known to have developed symptoms.

The wider outbreak remains severe. Ebola Tracker reported on October 21 that the DRC bulletin for October 20 recorded 9,704 confirmed cases and 4,687 deaths, a case fatality rate of 48.3 percent. The bulletin counted 2,595 recovered patients and 1,041 people hospitalised in Ebola treatment centres. It recorded 67 new confirmed cases and 41 deaths, in line with a seven-day average of 70.3 cases a day. The outbreak remained in 66 health zones across eight provinces, with no new health zone since October 16. Of the 41 deaths, 23 occurred in the community outside treatment centres and 18 in treatment centres.

The response indicators show where the gaps are. Ebola Tracker reported on October 21 that 3,795 alerts were received, 3,582 were checked and 663 were retained as suspected cases, while 67 of 462 samples tested positive, or 14.5 percent. Only 79.7 percent of contacts were seen by follow-up teams, below the 85 percent threshold INSP set for itself. Treatment centres held 65 patients per 100 beds, with North Kivu over capacity at 488 patients for 410 beds. Vaccination has reached 8,762 people with the Ervebo vaccine since the campaign began on August 26, 2026, but North Kivu has run out of vaccine stock.

Analysis

The most important fact about Nigeria's case is not the single diagnosis but the delay before it was reached. Ayoade Alakija, a Nigerian physician who co-chairs a G7 committee for investment in global health, said it took 12 days from the woman falling sick for her to be tested for Ebola, potentially exposing many others. Al Jazeera reported on October 21 that authorities do not believe she was symptomatic during the flight, but the gap between the first hospital visit and the Ebola test is the kind of window that allows an outbreak to seed new chains.

What this really means is that Nigeria's detection system worked, but late, and late detection is a warning rather than a clean bill of health. The country activated its incident management system, identified 44 contacts and put 46 people on a no-fly list, which are strong initial steps. Yet the patient had already visited two private hospitals before public health authorities were alerted. Ebola readiness cannot stop at airports and public treatment centres. It has to include private clinicians who may see a malaria-like illness and not ask about travel.

The bigger picture here is that the DRC outbreak is no longer a single-country emergency. The virus has reached Uganda, Kenya and now Nigeria, and the DRC's own response indicators are under strain. Contact follow-up at 79.7 percent is below target, North Kivu is treating more patients than its beds can hold, vaccine stock has run out in the most affected province and safe burials are being postponed. Those failures are the conditions that let a virus travel across borders.

Why It Matters

This is the first time the current outbreak has reached West Africa, and Nigeria is the fifth country to detect the virus. The movement changes the risk map for the region. A case in Abuja, even an imported one, means health workers in a major West African city are now part of the response, and airports, hospitals and laboratories across a wider area need to be ready. The 44 contacts and the 46 people barred from flights are a reminder that contact tracing is not a bureaucratic exercise. It is the main tool for stopping a virus that spreads through close contact with bodily fluids.

The absence of an approved Bundibugyo vaccine or treatment raises the stakes. Trials are under way, but they are not the same as ready supply. The DRC's 48.3 percent case fatality rate shows how dangerous this species can be, and the outbreak's 9,704 confirmed cases and 4,687 deaths show how much capacity the response has already consumed. Every new country that detects a case adds demand for laboratory tests, personal protective equipment, trained contact tracers and treatment beds. It also adds pressure on the same limited vaccine stocks that are already exhausted in North Kivu.

At the same time, WHO's advice against travel and trade restrictions is a warning against panic. The agency wants countries to strengthen surveillance and testing, not to close borders. Nigeria's airport screening, Cameroon's tighter port and airport monitoring, and Kenya's nine cases all point to one lesson: the response has to be regional.

Next Up

The next 21 days are the critical window for Nigeria. The 44 contacts are being monitored for symptoms, and no contacts are known to have developed symptoms so far. Investigators are still trying to establish the likely source of infection and reconstruct the woman's full travel and exposure history. WHO and partners are supporting case investigation, contact tracing and infection prevention and control. The 46 people on the no-fly list will remain restricted as officials watch for any sign that the chain has widened.

Beyond Nigeria, the focus will stay on the DRC, where the outbreak remains in 66 health zones across eight provinces. The response needs to raise contact follow-up above the 85 percent threshold, restore vaccine supply in North Kivu and improve safe burial and laboratory access in Ituri and Tshopo. Kenya's nine cases since October 6 will also be watched for further spread. The test for the region is whether Nigeria's imported case becomes a single contained event or the start of a wider West African cluster. The answer will depend on how quickly the next suspected case is tested, isolated and traced.

New Mexico judge orders Meta to pay $25 billion over Facebook data privacy deception

Yanming Liu — Thu, 22 Oct 2026 16:39:09 +0000

When the Cambridge Analytica revelations broke in 2018, they exposed how a now-defunct British political consulting firm had obtained personal data from as many as 87 million Facebook users through a third-party app and used it to generate targeted political advertising during the 2016 election season, when the firm worked for Donald Trump's campaign. The scandal produced a $5 billion FTC settlement in 2019 and a $725 million class action in 2022, but its legal aftermath keeps unfolding in state courthouses.

New Mexico's own case dates to 2021, when then-Attorney General Hector Balderas sued Meta. The state accused the company of lying to New Mexico users about who had access to their data and about how it handled hate speech and misinformation, and lawyers cited a 2010 Washington Post op-ed in which Mark Zuckerberg wrote that Facebook did not sell user data. The suit was carried forward by Balderas's successor, Attorney General Raul Torrez, who declined to join the multistate settlement Meta reached in August 2026.

The trial ran for two weeks earlier this year. On September 25, jurors in Santa Fe found that 26 of 29 statements made by the company and its leadership were misleading, and that Meta had committed more than 43 million violations of the state's Unfair Practices Act, a count calculated from the number of Facebook users or residents who were the audience for each statement. Jurors also found that the company had intentionally misled the public about how it benefited from hate speech and how rules against it were enforced.

What remained was the size of the penalty. At an October 1 hearing, state lawyer Randi McGinn asked for $35 billion to $40 billion, while Meta urged a cap of $3.45 billion and argued that a higher figure would violate due process. On Wednesday, October 21, 2026, Judge Francis Mathew of New Mexico's First Judicial District Court answered the question, and the answer was considerably larger than anything the company had proposed.

Key Facts

Mathew ordered Meta Platforms to pay $25 billion in civil penalties. State law allows a penalty of up to $5,000 per violation, and the 43,899,725 violations found by the jury produced a statutory total of $219.5 billion. Mathew found that a penalty of more than $219 billion was warranted, then reduced the figure to $25 billion. All of the money is directed to New Mexico's school system. CNBC reported on October 21, 2026 that interest on the penalty accrues at 15 percent each year until the fine is paid in full.

IAPP reported on October 22, 2026 that the order applies the maximum $5,000 per-violation figure to all 43,899,725 violations before reducing the total. Mathew wrote that the extraordinary number of willful violations, the duration and repetition of the conduct, the breadth of subjects on which violations occurred, the involvement of senior Facebook leadership, the size of New Mexico audiences reached and the clear intentional and systematic nature of the repeated misstatements all supported the maximum. BBC News reported on October 21, 2026 that the judge described the violations as willful and said they spanned more than 11 years, from 2010 to 2021, with communications between senior executives, including Zuckerberg, designed to mislead the public.

In the order, Mathew wrote that the wrongdoing went "to the heart of Facebook's core business practices" and related to the way in which the platform induces people onto it and ultimately keeps them there. He also wrote that Facebook did not conduct the comprehensive investigation that it promised after the Cambridge Analytica revelations, citing pressure from senior executives to keep costs down, inadequate enforcement resources and a desire not to create precedent. Al Jazeera reported on October 22, 2026 that the order landed more than three weeks after the jury's verdict.

Torrez said the result makes clear that no corporation is too powerful to be held accountable, and that the case is about whether corporations can mislead consumers about what happens to their personal information without facing meaningful consequences. He called the judgment one of the largest, if not the largest, single state verdict against a company in American history, and said that for too long powerful technology companies have operated as though their size and influence put them beyond the reach of the law.

Meta's chief legal officer, C.J. Mahoney, said the ruling makes it all but impossible to do business in the state of New Mexico and described the suit as, at its core, a tax on speech. He said the company is confident it will prevail on appeal. Reuters reported on October 21, 2026 that six other states settled Cambridge Analytica-related claims for $459.2 million as part of a $17.1 billion multistate settlement Meta reached in August 2026 over teen mental health. In March 2026, a Santa Fe jury in a separate case ordered Meta to pay $375 million in civil penalties over child safety, and a judge later directed $567 million into a New Mexico teen mental health fund.

Analysis

What this really means is that the most consequential privacy ruling against Meta in years turns less on surveillance itself than on the sentences the company wrote about surveillance. The 43,899,725 figure was not a tally of hacked accounts or scraped profiles. It was a count of statements multiplied by the audiences that saw them, calculated from the number of Facebook users or residents reached by each statement. That arithmetic converts a public relations problem into a balance sheet problem, and it hands state attorneys general a reusable template.

The judge's own math shows how the leverage works. Mathew accepted the statutory maximum of $5,000 per violation, which produced $219.5 billion, then reduced the award by nearly $195 billion to reach $25 billion. The reduction acknowledges the due process argument Meta pressed, that anything above $3.45 billion would be unconstitutional, while still leaving a figure roughly equal to Meta's quarterly profit. BBC News reported on October 21, 2026 that Meta's revenue rose 26 percent year on year to $64.5 billion in the July to September quarter and that profit tripled to $9.8 billion. A $25 billion judgment is not an existential sum for the company, but it is a persistent one, especially with interest compounding at 15 percent a year while appeals run.

The bigger picture here is that New Mexico deliberately chose a different route from its peers, and on paper it is now far ahead of them. Six other states resolved Cambridge Analytica-related claims for $459.2 million inside a $17.1 billion multistate package that also covered teen mental health allegations. Torrez skipped that deal. The result is a court judgment rather than a negotiated release, which means the number is both larger and less certain, since a single appellate panel can reduce or vacate it.

Whether the amount survives is a separate question from whether the underlying finding is sound. Mahoney's description of the lawsuit as a tax on speech previews the constitutional argument Meta will press, and the verdict's reliance on statements made to the public, including a 2010 op-ed, gives that argument its opening. Still, the factual findings are unusually detailed: 26 of 29 statements deemed misleading, a finding of intent on hate speech disclosures as well, and a documented failure to conduct the investigation the company promised. Courts reviewing penalties generally defer to findings of willfulness, and this record is built almost entirely from Meta's own words.

Why It Matters

The direct consequence is financial and local. Roughly two million New Mexicans were described by state lawyers as affected, and every dollar of the $25 billion is earmarked for the state's school system rather than its general fund. That design gives the judgment a political constituency most corporate penalties lack. It also compounds the state's existing recoveries from Meta: $375 million in civil penalties over child safety from a March 2026 jury, and a later $567 million directed into a New Mexico teen mental health fund.

The wider consequence is doctrinal. IAPP reported on October 22, 2026 that the decision is the latest example of state enforcers using consumer protection law to pursue privacy claims, following the FTC's 2019 settlement, the 2022 class action and the August 2026 multistate deal. That sequence matters because consumer protection statutes carry per-violation penalties that privacy statutes often do not, and they let a single state generate exposure measured in tens of billions of dollars. Torrez said the judgment should be a signal, an unambiguous message, to Silicon Valley.

There is also a transparency dimension that outlasts the litigation. The case was built on the gap between what Facebook told users and what its executives discussed internally, and Mathew's findings describe a company that promised a comprehensive investigation after the Cambridge Analytica revelations and then did not conduct one, citing cost pressure, thin enforcement resources and a reluctance to set precedent. Whatever an appellate court does with the $25 billion, that narrative is now a matter of judicial record, and it will be cited in the state cases still to come.

Next Up

Meta intends to appeal, and Mahoney has said he expects to win. Until the judgment is resolved, interest accrues at 15 percent each year, so the exposure grows the longer the company litigates. The appellate court will have to weigh New Mexico's per-violation scheme against Meta's due process objection, and it will do so with the judge's reduction from $219.5 billion already on the record as evidence that the trial court considered proportionality.

Other proceedings continue in parallel. Al Jazeera reported on October 22, 2026 that a trial began in August in a California federal court, brought by a coalition of 29 state attorneys general over addictive design for children, addressing claims that Meta illegally collected and used children's data. New Mexico has already shown it will litigate rather than settle, and other states now have a detailed public template if they choose to follow.

Don't Nod Opens French Safeguard Proceedings as Cash Falls to 9.9 Million Euros

Yanming Liu — Wed, 21 Oct 2026 15:50:15 +0000

Don't Nod Entertainment SA, the Paris-based studio known for the first two Life is Strange games, Jusant, Banishers: Ghosts of New Eden, Lost Records: Bloom & Rage and Aphelion, has moved to protect itself from creditors after its cash position fell to €9.9 million at the end of June 2026. On October 19, 2026, the Paris Business Court granted the company's request to open safeguard proceedings, a French insolvency procedure that freezes liabilities incurred before the ruling and gives the studio an initial six-month observation period to seek external financing and reshape its French operations. The decision was disclosed in the company's 2026 half-year results, published on October 20, 2026 and approved by its board the previous day.

The filing follows a difficult stretch for a studio that once helped define the narrative adventure genre. PC Gamer reported on October 20, 2026 that Don't Nod has struggled since 2024, when Jusant and Banishers: Ghosts of New Eden sold well below expectations despite good reviews, and that work on two new games was paused and layoffs followed in 2025. The same report noted that the company warned a month before the safeguard filing that it might not have enough cash to get through January 2027 and that up to 90 people were at risk of layoffs. The studio's recent releases, including Lost Records: Bloom & Rage and Aphelion, have not generated the commercial cushion needed to absorb those setbacks.

French safeguard proceedings are not the same as liquidation. PC Gamer reported on October 20, 2026 that the procedure is roughly comparable to US Chapter 11, citing advisory firm Hectelion, which describes it as a preventive French insolvency process for companies not yet in payment default but facing difficulties they cannot overcome alone. The debtor initiates the process, and an observation period of 6 to 18 months suspends creditor enforcement while a debt reduction and rescheduling plan of up to 10 years is negotiated and approved by a court. Shacknews reported on October 20, 2026 that the Paris Business Court granted Don't Nod's request and that the move essentially freezes liabilities and gives the company time to formulate a plan.

The immediate human stakes are clear. Don't Nod's September 1, 2026 transformation plan refocuses French operations on a single production line, with no impact on Montreal, and could lead to workforce adjustments affecting up to 85 positions in France. In its judgment dated October 19, 2026, the court appointed SELARL DÉTROIT, represented by Maître Charles-Henri Carboni, as court-appointed administrator. The combination of court protection, a narrower French production footprint and a search for outside money defines the next phase for one of France's most recognizable independent game developers.

Key Facts

Don't Nod reported on October 20, 2026 that H1 2026 revenue was €6.1 million, down 14% year on year. Total operating revenue fell 56% because no capitalized production costs were recognized in the period. Operating EBITDA including French and Canadian tax credits was negative €4.3 million, compared with negative €2.0 million in H1 2025. Operating EBIT was negative €7.3 million and the consolidated net loss was €7.1 million. Personnel expenses fell 34% to €8.2 million, a sign that cost reductions were already underway before the court filing.

Cash and equivalents stood at €9.9 million at the end of June 2026, down from €15.5 million at December 31, 2025. Free cash flow was negative €5.2 million and cash burn was €5.6 million. The company stated that its ability to continue operations over the next 12 months depends on securing external financing and that this creates material uncertainty about its ability to continue as a going concern beyond January 31, 2027. That warning is central to the safeguard request, because the procedure buys time but does not by itself supply new money.

Sales of €3.5 million came mainly from PlayStation Plus and Game Pass for Lost Records: Bloom & Rage, initial sales of Aphelion and its Game Pass inclusion, plus back catalogue. Aphelion sales came in below group expectations. Development revenue of €2.6 million came from the Montreal team's narrative game based on a major Netflix IP. The split matters because it shows a company leaning on subscription deals, back catalogue and work for a partner in Canada while its own new premium releases underperform.

The court's judgment opened an initial six-month observation period and froze liabilities incurred before the ruling for the duration of the proceedings. Shacknews reported on October 20, 2026 that CEO and chairman Oskar Guilbert said the company's poor cash position does not allow it to cover the costs of all its operations and projects, even after cost savings and the Netflix partnership in Canada. Guilbert described the video game industry as facing an exceptionally challenging environment marked by highly selective access to financing, and he called the application proactive and intended to build a sustainable solution while acknowledging the impact on employees affected by planned organizational changes.

Analysis

What this really means is that Don't Nod has moved from a cost-cutting story to a survival story with a court deadline attached. Safeguard proceedings are designed to preserve the business as a going concern, not to shut it down, and the appointment of an administrator does not remove management from day to day control. But the procedure only works if the studio can convert six months of protection into a credible financing package and a plan that creditors and the court can accept. The €9.9 million cash balance is not enough to fund a multi-project pipeline through January 2027 without new money, especially after negative free cash flow of €5.2 million in the first half alone.

The bigger picture here is that Don't Nod's problem is not simply one weak game. PC Gamer reported on October 20, 2026 that Jusant and Banishers: Ghosts of New Eden sold well below expectations in 2024, and that Aphelion sales came in below the group's expectations in 2026. The company has responded with layoffs, a narrower French production line and a reliance on Montreal's Netflix project, but those moves have not yet changed the cash trajectory. A safeguard filing can stabilize the balance sheet in the short term by stopping creditor enforcement, yet it cannot fix a release slate that is not generating enough revenue to cover development and personnel costs.

The French procedure also gives Don't Nod a different kind of runway than a US Chapter 11 case. PC Gamer reported on October 20, 2026 that the observation period can last from 6 to 18 months and that a debt rescheduling plan of up to 10 years may be negotiated. That is a long window by game industry standards, but it is still a window. Vertical Slice reported on October 20, 2026 that the court appointed Selarl Detroit as administrator and that the half-year operating loss was €4.3 million, almost double the €2 million loss a year earlier. The administrator's role will be to test whether the transformation plan is realistic, whether outside financing exists and whether the French workforce can be reduced to a size the business can support.

The judgement on the studio's creative future is necessarily more cautious. Don't Nod still owns recognizable IP and has a Montreal team doing work for a major Netflix IP, which gives it assets that a pure liquidation would destroy. But the company's own half-year report ties survival to external financing, and its cash position does not cover all requirements. What this really means is that the next six months are less about announcing new games than about proving that the remaining production line, the Montreal operation and the back catalogue can support a smaller, financially stable company.

Why It Matters

Don't Nod is one of the clearest examples of the squeeze facing mid-sized independent studios in 2026. The company has a recognizable brand, a history of acclaimed narrative games and a partnership with Netflix in Canada, yet it still reached a point where the Paris Business Court had to freeze pre-ruling liabilities to keep creditors at bay. Shacknews reported on October 20, 2026 that the move is framed as a plan to try to stay in business rather than a liquidation, but the report also stresses that the company is in a dire position. That combination of recognizable IP and fragile cash flow is not unique to Don't Nod, which is why the case matters beyond its own employees and players.

The workforce impact is concrete. Up to 85 positions in France could be affected under the September 1, 2026 transformation plan, which refocuses French operations on a single production line. The Montreal team is not affected by that plan and is generating development revenue from a narrative game based on a major Netflix IP. For the French game industry, the safeguard proceedings test whether a studio can use the country's insolvency framework to preserve creative capacity while shrinking its cost base. For employees, the court's six-month observation period is a period of uncertainty, not a guarantee of continuity.

The outcome also matters to players and platform partners. Lost Records: Bloom & Rage found revenue through PlayStation Plus and Game Pass, and Aphelion was included in Game Pass, which shows that subscription services are part of the studio's commercial model. If Don't Nod cannot secure financing, those partnerships and the back catalogue may be worth less inside a distressed company. If it can, the studio may emerge with a narrower slate and a stronger balance sheet, but the transition will be judged by what happens to the people who make the games.

Next Up

The first milestone is external financing. Don't Nod has said its ability to continue operations over the next 12 months depends on securing new money, and the court has opened an initial six-month observation period that runs from the October 19, 2026 judgment. The administrator, SELARL DÉTROIT, will work with management on a continuation plan while liabilities incurred before the ruling remain frozen. Investors, creditors and employees will be watching for a financing commitment, a revised budget and a clearer timeline for the French workforce adjustments.

The second milestone is the going concern test beyond January 31, 2027. The company's half-year report states that material uncertainty exists about its ability to continue as a going concern beyond that date, and the safeguard procedure does not remove that uncertainty by itself. Don't Nod will need to show progress on financing, on the French production refocus and on the Montreal Netflix project before the observation period ends. If those pieces come together, the studio has a path to a smaller but viable future. If they do not, the court process will move from protection toward a harder restructuring.

FDA approves GSK's Hibsago, first antisense oligonucleotide for chronic hepatitis B

Yanming Liu — Wed, 21 Oct 2026 15:48:51 +0000

The U.S. Food and Drug Administration announced on October 20, 2026 that it approved Hibsago (bepirovirsen) injection for adults with chronic hepatitis B virus infection who do not have cirrhosis. It is the first antisense oligonucleotide ever approved for the disease and is cleared for use with existing antiviral therapy. The label covers adults who have taken hepatitis B antiviral therapy for at least six months, have suppressed virus levels in the blood and have hepatitis B surface antigen levels of 3,000 IU/mL or less on an FDA authorized test. Hibsago is injected under the skin for up to 24 weeks, and patients continue their existing hepatitis B medicine for at least 24 weeks after the last injection.

Chronic hepatitis B is a serious liver infection that spreads through infected bodily fluids such as blood, saliva and semen. GSK said it affects about 1.7 million people in the United States and more than 240 million worldwide, causes roughly 1.1 million deaths a year and remains the leading cause of liver cancer. Reuters reported on October 20, 2026 that more than 250 million people globally live with the infection. Existing nucleotide analogue treatments are often taken for life. They suppress the virus but rarely eliminate it. GSK said the current standard of care typically achieves less than 1% functional cure after one year, while Reuters put sustained clearance at 1% to 4%.

Functional cure means reducing viral DNA and proteins to undetectable levels, not eradicating every trace of the virus, as Fierce Pharma reported on October 21, 2026. Antisense technology is designed to interfere with the genetic instructions that let the virus reproduce and produce viral proteins. GSK licensed bepirovirsen from Ionis Pharmaceuticals, which is eligible for milestone payments, according to Reuters. The drug is already approved in Japan, where the Ministry of Health, Labour and Welfare cleared it in late August 2026, and it is under review in China and Europe.

The approval rests on the B-Well phase III program. GSK announced on October 20, 2026 that B-Well 1 and B-Well 2 were randomized, double blind, placebo controlled trials in 29 countries. Pooled data showed a 19% functional cure rate, or 233 of 1,220 participants, versus 0 of 614 on placebo at week 72. In a key secondary endpoint, the rate was 26%, or 200 of 768, among participants with baseline surface antigen at or below 1,000 IU/mL, a group representing about 45% of diagnosed chronic hepatitis B cases globally.

Key Facts

The FDA said 24% of Hibsago recipients across two placebo controlled trials met the requirements to stop their existing medicine, versus none on placebo. Twenty four weeks after stopping all hepatitis B treatment, 19% still had the virus under control and no detectable surface antigen. The label carries a boxed warning for serious liver reactions and low platelet counts that can cause life threatening bleeding, plus warnings for worsening kidney function, serious inflammatory reactions such as vasculitis and risks from improper administration. The most common side effects, excluding laboratory abnormalities, were injection site reactions, fever, fatigue and headache. The FDA also authorized the Roche Elecsys HBsAg II quant II RxDx assay as a companion diagnostic to select and monitor patients.

GSK announced on October 20, 2026 that the course is six months, with an option for self administration after the first dose. Exploratory analyses showed bepirovirsen reduced surface antigen to 100 IU/mL or less in 49% of participants, or 598 of 1,220, and in 62% of the lower antigen subgroup, or 476 of 768, as of week 72. GSK described bepirovirsen as a first in class antisense oligonucleotide offering functional cure rates that it called unprecedented compared with current treatment.

Reuters reported on October 20, 2026 that GSK expects peak annual sales of more than £2 billion, or $2.68 billion, for Hibsago, central to its plan to reach more than £40 billion in annual revenue by 2031. Under new chief executive Luke Miels, GSK is trying to speed development and launches ahead of patent expirations on its blockbuster HIV medicines. Reuters also reported that U.S. biotech Aligos Therapeutics is developing a rival therapy, pevifoscorvir sodium, in a mid stage trial. GSK did not immediately respond to a Reuters request for comment on U.S. pricing and commercial availability.

Fierce Pharma reported on October 21, 2026 that the FDA gave the go ahead late Tuesday for use with nucleos(t)ide analogue reverse transcriptase inhibitor therapy in adults without cirrhosis. The publication said the approval brings the antisense oligonucleotide class to hepatitis B for the first time and that the boxed warning could slow adoption. It noted that standard of care nucleoside analogues such as Bristol Myers Squibb's Baraclude and Gilead Sciences' Viread block viral replication but have limited potential to deliver a functional cure. NDTV reported on October 21, 2026 that the FDA approval applies to adults without cirrhosis who have received antiviral therapy for at least six months and have surface antigen levels of 3,000 IU/mL or less.

Analysis

What this really means is that the standard of care for chronic hepatitis B has moved from indefinite suppression alone to a time limited attempt at functional cure for a carefully selected group. The 19% absolute functional cure rate is far below the efficacy seen with many curative regimens in other diseases, but it is a genuine advance against a baseline of zero in the placebo arms and a standard of care that GSK says typically achieves less than 1% functional cure after one year. The 26% rate in patients with baseline surface antigen at or below 1,000 IU/mL is the more clinically relevant number because it identifies the population most likely to benefit. The approval does not mean that most patients will be cured. It means that some patients may be able to stop all hepatitis B treatment without losing viral control.

The label and the warning language will shape adoption as much as the efficacy data. Hibsago is restricted to adults without cirrhosis, with suppressed virus and surface antigen at or below 3,000 IU/mL, and it requires an FDA authorized test to establish eligibility. The boxed warning for serious liver reactions and low platelet counts that can cause life threatening bleeding, plus warnings for worsening kidney function, serious inflammatory reactions such as vasculitis and improper administration, means that patients will need regular blood tests and follow up. Those are manageable for many patients, but they add monitoring burden to a disease that is often managed with generic oral antivirals.

For GSK, the judgement is that Hibsago is strategically important but not an immediate blockbuster without pricing and access clarity. Reuters reported on October 20, 2026 that GSK projects peak annual sales above £2 billion and did not comment on U.S. pricing or near term launch plans. The product is central to GSK's plan to reach more than £40 billion in annual revenue by 2031, and it gives the company a first in class asset as it faces patent expirations on HIV medicines. The Ionis milestone obligations and the Roche companion diagnostic add complexity to the commercial model. Approvals in Japan and reviews in China and Europe give GSK multiple markets, but each will have its own label and reimbursement negotiation.

Why It Matters

The public health stakes are large. GSK said chronic hepatitis B affects about 1.7 million people in the United States and more than 240 million worldwide, causes roughly 1.1 million deaths a year and remains the leading cause of liver cancer. Reuters put the global population at more than 250 million. Current nucleotide analogues are often taken for life and help only 1% to 4% of patients clear the virus for a sustained period, according to Reuters. A six month course that allows some patients to stop all treatment could reduce the cumulative burden of lifelong therapy for a subset of patients.

The approval also matters because it validates antisense oligonucleotides as a treatment modality in infectious disease. The FDA said Hibsago is the first antisense oligonucleotide approved for chronic hepatitis B. GSK licensed the drug from Ionis, and the approval triggers milestone payments. For patients, the practical message is that Hibsago is not a first line option for everyone with hepatitis B. It is for adults without cirrhosis who are already on antiviral therapy, have suppressed virus and have surface antigen at or below 3,000 IU/mL. Wendy Carter, acting director of the Office of Infectious Diseases in the FDA Center for Drug Evaluation and Research, said Hibsago offers some patients the possibility of maintaining control after all treatment has ended and called the approval an important advance.

Next Up

The next step is the U.S. launch. GSK did not comment to Reuters on near term launch plans or U.S. pricing, and those details will determine access. The company is also awaiting regulatory decisions in China and Europe, while Japan has already approved the product. GSK's sales forecast of more than £2 billion at peak will depend on label uptake, diagnostic availability and reimbursement. The approval includes a boxed warning and requires regular blood tests and follow up, so specialty liver clinics will need workflows for patient selection, injection training and monitoring.

Australia Prepares Federal Court Case Against Meta, TikTok, Snap and YouTube

Yanming Liu — Wed, 21 Oct 2026 15:48:50 +0000

Australia is preparing to take five of the world's most widely used social media services to the Federal Court over its under-16 ban, turning a landmark child safety law into a live legal confrontation with some of the largest technology companies. Communications Minister Anika Wells told Bloomberg on 20 October 2026 that the eSafety Commissioner was gathering evidence for proceedings against Facebook, Instagram, TikTok, Snapchat and YouTube. No case had been filed at the time of the report.

The dispute centres on a law that took effect on 10 December 2025 and made Australia the first country to impose a nationwide minimum age for social media accounts. It requires providers of age-restricted social media platforms to take reasonable steps to prevent Australian children under 16 from having accounts. The eSafety Commissioner opened compliance investigations into the five services in March 2026 after first casting a wider net across ten platforms.

The regulatory background matters because the government's case will not rest simply on the fact that some teenagers still hold accounts. A July 2026 eSafety report found most under-16s were still able to keep existing accounts or create new ones, largely because age verification measures were ineffective. The government responded by doubling the maximum penalty for breaches to A$109.2 million, about US$76 million, and by expanding the regulator's powers to compel documents and question current and former employees.

The platforms reject the charge that they are ignoring the law. Meta said in August 2026 that it had removed access to more than 750,000 Facebook and Instagram accounts in Australia judged to belong to under-16s, using artificial intelligence to scan posts, biographies and captions for age clues. It also argued there should be a single reliable age signal delivered at the operating system or app store level. That argument is likely to sit at the centre of the courtroom fight over what counts as reasonable steps.

Key Facts

The five services named by Wells are Facebook and Instagram, both owned by Meta Platforms, TikTok, Snapchat and YouTube, which is owned by Alphabet's Google. The eSafety Commissioner is Julie Inman Grant. Wells said the commissioner now has stronger powers to gather the evidence she needs to take those five companies to the Federal Court and is using those powers to prepare her case. The minister confirmed that no case had been filed when Bloomberg published its interview.

eSafety's March 2026 compliance update set out the enforcement baseline. The regulator said it was focusing on ten platforms and had issued 23 information gathering notices to those platforms. It then narrowed formal investigations to five: Facebook, Instagram, Snapchat, TikTok and YouTube, aiming to decide on enforcement action by the middle of 2026. The update also noted that civil penalties then available were up to A$49.5 million, before the government doubled the maximum.

The July 2026 findings gave the government its main factual foundation. eSafety's compliance update reported a survey of 898 parents in late January 2026 which found about a third of children still had social media accounts, down from half before the ban. Among under-16s who had accounts before the ban, 60 to 70 per cent had kept Facebook, Instagram, Snapchat or TikTok accounts, while just under 50 per cent still had YouTube. The regulator listed poor practices including allowing underage users to retry age checks until they passed, doing too little to stop removed teenagers from reopening accounts, and lacking clear reporting paths for parents.

The political case was sharpened at the National Press Club of Australia on 15 October 2026. The Financial Register reported on 15 October 2026 that Wells said half of the young people surveyed who still had a social media account three months after the minimum age law started had never been asked to verify their age, citing an eSafety survey. She said more than 5 million underage accounts had been deactivated, removed or restricted, and that a first eSafety survey three months after the law started found a 20 per cent reduction in under-16 account holders.

Wells has used the same platform to argue that the law itself is sound and that the failure lies with the companies. The Financial Register reported on 15 October 2026 that she told the National Press Club: 'The law is not failing. Platforms are failing to comply with the law.' She added that the eSafety Commissioner's investigations were painstaking and that the results were not good enough. Her remarks came as the government introduced the Digital Duty of Care bill into Parliament and as it sought to show that enforcement would follow the original ban.

Analysis

What this really means is that the Federal Court case will turn less on whether children can still find ways around age checks than on whether the platforms built systems that were reasonably designed to stop them. eSafety's March 2026 update made that distinction explicit, saying enforcement requires evidence of systemic failure rather than proof that some children still hold accounts. That standard gives the regulator a difficult but focused task: it must show that the companies' age assurance, account removal and re-registration controls failed in a systemic way, not merely that determined teenagers found gaps.

TechRepublic reported on 21 October 2026 that the legal action would be the biggest enforcement test of Australia's world first minimum age law. The report noted that the cases will test what counts as reasonable steps and that internal records on age checking systems could become central evidence. That is why the expanded powers matter. New investigative powers effective in September 2026 let the regulator demand relevant documents and summon current or former employees for questioning. The commissioner's ability to obtain internal design documents, risk assessments and decision records may matter more than any single public statement from a platform.

The companies have a ready defence. Meta's August 2026 statement that it had removed access to more than 750,000 Facebook and Instagram accounts in Australia judged to belong to under-16s is intended to show that it took concrete action at scale. Its call for a single reliable age signal at the operating system or app store level shifts part of the responsibility to Apple, Google and other gatekeepers, though the law as described places the obligation on social media providers to take reasonable steps. The regulator's counter is likely to be that platforms controlled the sign up and login process, could have designed stricter checks, and too often allowed underage users to retry age checks until they passed.

The bigger picture here is that Australia is trying to establish a compliance model for the rest of the world, and the court case is the point at which the model becomes testable. Bloomberg reported on 20 October 2026 that the maximum penalty has been doubled to A$109.2 million, about US$76 million, and that the regulator can compel documents and question current and former employees. Those figures and powers are meant to give the case weight beyond a public warning. If the commissioner cannot translate them into findings of systemic failure, the practical meaning of the ban could be diluted even if the law remains on the statute book.

Why It Matters

The outcome will shape how far other governments believe a minimum age law can be enforced. The Financial Register reported on 15 October 2026 that Brazil, Malaysia, Gabon, Indonesia and the United Arab Emirates had put their own laws in place since Australia's started, with the United Kingdom and Turkey expected to follow in coming weeks. The Next Web reported on 20 October 2026 that Wells is assembling a coalition of countries on child safety, with talks held with counterparts in Malaysia, the Philippines, New Zealand, Canada, Sweden and the UK. A credible Federal Court case would strengthen that push; a weak one would give platforms a template for resisting similar rules elsewhere.

The case also matters for the division of responsibility in the technology stack. Platforms argue for a single reliable age signal at the operating system or app store level, which would move the first line of age assurance away from individual apps. Australia's law, as described by eSafety, still requires social media providers to take reasonable steps to prevent under-16s from having accounts. The court will have to decide how much weight to give to platform level checks, parental controls, device level signals and the practical difficulty of detecting users who lie about their age. That decision could influence product design well beyond Australia.

There is a broader child safety agenda attached to the enforcement push. The Next Web reported on 20 October 2026 that Wells's template is the Digital Duty of Care bill introduced in the week before, which would require digital services including AI chatbots to protect under-18s and would carry fines of up to A$109.2 million, about US$76.2 million. Wells wants it passed by the end of 2026, taking effect 12 months later, and the Trump administration has objected to the bill. The Financial Register reported on 15 October 2026 that eSafety estimates one in five Australian children using AI tools, around 180,000 children, has had a potentially harmful interaction. The under-16 case therefore sits inside a wider argument about platform duties, not a single narrow rule.

Next Up

The immediate question is whether and when the eSafety Commissioner files proceedings in the Federal Court. As of 20 October 2026 no case had been filed, and Wells described the commissioner as using her powers to prepare the case. The next public milestones are likely to be the filing itself, the scope of the claims against each of the five services, and the evidence the regulator seeks to compel from the companies. Each platform may respond separately, and the court will have to weigh differing compliance records across Facebook, Instagram, TikTok, Snapchat and YouTube.

In parallel, the government will keep pressing the Digital Duty of Care bill and its international coalition. The Next Web reported on 20 October 2026 that Wells wants the bill passed by the end of 2026 and taking effect 12 months later. If that timetable holds, Australia will have added a second layer of regulation before the first under-16 court case has produced a final judgment. For the platforms, the practical choice is whether to keep arguing that they are complying, as Meta did in August 2026, or to adjust their age assurance systems before the Federal Court sets the standard.

Supercell completes full takeover of Merge Mansion maker Metacore

Yanming Liu — Tue, 20 Oct 2026 15:42:22 +0000

Supercell has spent most of its history as a company that grows its own games and hands them to small teams that run them for years. That portfolio now includes a title it did not build. On October 19, 2026, the Helsinki publisher completed its purchase of Metacore, the fellow Finnish studio behind Merge Mansion, taking 100 percent ownership and folding the merge puzzle game into its live games portfolio alongside Hay Day.

Metacore was not a stranger to Supercell. The studio, which began life as Everywear Games before rebranding in 2020, launched Merge Mansion that same year: a merge-2 mystery puzzle game in which players renovate a neglected family estate while uncovering its secrets. Supercell backed the effort early, putting EUR 25 million (about $29.6 million) into the company in 2020 and later agreeing a $180 million (EUR 150 million) credit line in 2021 to help it scale the game. By the time acquisition talks became public, Supercell was already Metacore's largest shareholder.

The relationship also had a failed experiment behind it. In January 2023, Metacore took over Everdale, a Supercell game that had stalled in soft launch, and tried to rework and relaunch it. The studio killed the game in September 2024, a detail worth remembering now.

The deal itself moved slowly in public. Supercell announced in May 2026 that it intended to buy the remainder of Metacore and bring Merge Mansion into its live games portfolio. On August 31, 2026, Supercell said the deal had been signed and was expected to complete by the end of September. The confirmation of the close only arrived on October 19, roughly three weeks later than that target, with Metacore writing on LinkedIn that the acquisition "has been closed" and Supercell posting that the Merge Mansion team "has moved in".

Key Facts

PocketGamer.biz reported on October 19, 2026 that Supercell had closed its purchase of the Finnish studio, taking 100 percent ownership of the Merge Mansion maker, with the exact terms of the transaction undisclosed. The report said Metacore's games team had officially started their journey as Supercellians and would continue to develop Merge Mansion with the stated aim of returning the casual game to its chart-topping spot.

Mobilegamer.biz reported on October 19, 2026 that Metacore is now fully owned by Supercell and that the studio had cut 159 staff at its Helsinki headquarters while closing offices in Germany and Sweden. The same report, citing AppMagic estimates, put Merge Mansion's lifetime earnings at around $490 million since its 2020 launch, and noted that former Small Giant Games CEO Jose Saarniniemi joined as general manager of Merge Mansion in June 2026.

GamesIndustry.biz reported on May 6, 2026 that Merge Mansion had been downloaded by more than 60 million players, and that Metacore claimed the game had generated around $700 million. The article quoted Supercell CEO Ilkka Paananen saying that Merge Mansion "has a strong core that players have genuinely loved for over five years", and that he believed its best days were still ahead.

PocketGamer.biz reported on May 5, 2026 that up to 160 roles were put at risk in Finland as part of a restructuring focused on Merge Mansion, and that Metacore was reviewing operations in Germany and Sweden. Metacore CEO Mika Tammenkoski said the company had built an organisation around growth ambitions that did not materialise, and that competition in the merge-2 space had intensified every year since launch, with Gossip Harbor and Travel Town proving particularly successful.

Supercell said in an announcement dated August 31, 2026 that the deal had been signed with completion expected by the end of September 2026, that terms would not be disclosed, and that for players the game would continue as normal. Sara Bach, President of Supercell, described Merge Mansion as a game that created a completely new genre, citing a strong brand, a passionate player community and unique gameplay and narrative.

Analysis

The financial logic is easier to read than the headline suggests. Merge Mansion has been downloaded more than 60 million times and has earned somewhere between roughly $490 million, per AppMagic estimates cited by Mobilegamer.biz, and the roughly $700 million Metacore itself has claimed. The gap between those two figures is wide enough to matter, and it is a reminder that self-reported lifetime revenue and third-party estimates rarely agree. What is not in dispute is the shape of the curve: Tammenkoski himself conceded that growth had plateaued, and that Metacore's new game investments had not succeeded in launching anything globally.

What this really means is that Supercell has bought a turnaround project rather than a growth engine, and it has bought it cheaply in organisational terms. The restructuring that accompanied the deal removed up to 160 roles in Finland, with 159 confirmed cuts at the Helsinki headquarters, and shut offices in Germany and Sweden. That is a studio being reduced to the one asset that still works. The arrival of Jose Saarniniemi, the former Small Giant Games CEO, as general manager of Merge Mansion in June 2026 fits the same pattern: a live operations specialist installed to run a single game with a loyal audience.

The competitive picture explains the urgency. Since Merge Mansion launched in 2020, the merge-2 category has filled with rivals, and Tammenkoski named Gossip Harbor and Travel Town as particularly successful. Supercell's argument, made repeatedly by Paananen, is that its live operations and user acquisition machinery can push a plateaued game back up the charts. That is credible from a company that has kept Hay Day running for over a decade, but it is also the standard acquirer's promise. The difference is that Supercell has owned a large slice of this studio for years, has already run one joint project into the ground with Everdale, and is therefore buying something it has had every opportunity to fix.

The bigger picture here is consolidation inside Finnish mobile gaming, executed by the country's most successful exporter and financed from its own balance sheet. Supercell provided a EUR 25 million investment in 2020 and a $180 million credit line in 2021, and now it has taken the whole company. Whether that reads as patient capital or as a slow-motion foreclosure depends on the outcome, and the outcome will be measured in chart positions rather than in press releases.

Why It Matters

For players, the practical answer is that little changes immediately. Supercell said the game continues as normal, and the same team is developing it. But ownership changes what a game is allowed to become. Merge Mansion now sits inside a portfolio that Supercell actively operates, and its roadmap will be judged against the standards of a company that expects its live games to run for many years. The stated ambition, returning the game to its chart-topping spot, is not a modest one for a title whose growth had plateaued.

For the Finnish development scene, the close is a sober data point. Metacore raised significant capital from Supercell, scaled a headquarters in Helsinki, opened offices in Germany and Sweden, and then cut 159 roles and retreated to a single game. That is a familiar arc in mobile free-to-play, in a country that has produced an unusually dense cluster of successful studios. The talent released by the restructuring will disperse into that cluster.

For Supercell, the deal tests a proposition the company has made before: that its live operations capability is transferable to games it did not design. Hay Day is the precedent it points to. Everdale is the counterexample. Merge Mansion, with 60 million downloads behind it and a brand strong enough that Supercell's president describes it as having created a completely new genre, is the case that will settle the argument.

Next Up

The immediate test is retention and revenue rather than announcements. Watch whether Merge Mansion returns to the top of the merge-2 charts in the months after the transition, and whether Supercell's user acquisition spending shows up in download estimates from firms such as AppMagic. Watch too for how Saarniniemi's team is staffed after the cuts, since a game being pushed back up the charts needs live operations capacity, not just a roadmap.

The wider question is whether this is a one-off or the start of a pattern. Supercell has absorbed a studio it had already financed twice, while promising to do what Metacore could not. If Merge Mansion climbs, other plateaued mid-size mobile studios with strong brands will look like acquisition candidates for large publishers with live operations expertise. If it does not, the lesson will be that 60 million downloads are not the same thing as a growth curve.

FDA grants accelerated approval to GSK dostarlimab as first immunotherapy for rectal cancer

Yanming Liu — Tue, 20 Oct 2026 15:41:03 +0000

For decades, the standard course of treatment for locally advanced rectal cancer has run through a fixed sequence: chemotherapy, then radiation, then surgery to remove part of the rectum. The regimen helps many patients, but it also leaves a lasting mark, with changes to bowel, urinary and sexual function, risks of secondary cancers and the possibility of infertility. A small subset of tumors carries a biomarker that has now opened a different route entirely, one that in most trial patients required none of those three interventions.

Those tumors are described as mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H). Their DNA repair defects leave them carrying an unusually heavy load of mutations, which makes them visible to the immune system. Dostarlimab, which GSK sells as Jemperli, is a PD-1 inhibitor that lifts a brake on T cells so they can attack the tumor.

On October 19, 2026, the US Food and Drug Administration granted accelerated approval to Jemperli (dostarlimab-gxly) as a single agent for adults with previously untreated stage II or stage III locally advanced rectal cancer that is dMMR or MSI-H, as confirmed by an FDA-authorized test. The agency framed the announcement around what the drug may let patients avoid: chemotherapy, radiation and surgery. It is the first immunotherapy approved specifically for this biomarker-defined rectal cancer population.

Accelerated approval is a conditional pathway. It allows the FDA to clear a drug on the basis of an intermediate or surrogate endpoint when the disease is serious and the need is unmet, on the understanding that confirmatory data will follow. For patients and clinicians, that distinction matters as much as the headline.

Key Facts

The evidence comes from AZUR-1 (NCT05723562), a multicenter, single-arm, open-label phase 2 study in 154 patients with previously untreated, histologically confirmed MSI-H or dMMR stage II or III locally advanced rectal cancer. Everyone enrolled received dostarlimab at 500 mg intravenously every three weeks for nine cycles, roughly six months of therapy. Tumor response was checked by endoscopy, rectal MRI and CT scans at week 6, week 12 and about three weeks after the last dose. Patients who reached a clinical complete response moved into non-operative management, with surveillance every four months for two years and every six months after that.

The disposition numbers carry much of the story. The ASCO Post reported on October 19 that 110 of 154 patients (71%) received dostarlimab alone, needed no additional treatment and did not progress. Twenty-six patients (17%) went on to surgery, 13 (8%) received additional systemic therapy or radiation, one (0.6%) had progressive disease, and four (2.5%) withdrew or were lost to follow-up.

Response rates depend on who measures them, and the agency published both versions. Investigator-assessed sustained clinical complete response at 12 months, known as cCR12, was 68% (98 of 144 evaluable patients, 95% CI 60 to 76), with an objective response rate of 82% (95% CI 75 to 88). Independent central review put cCR12 at 47% (54 of 116 patients, 95% CI 27 to 56) and the objective response rate at 79% (95% CI 71 to 85). Another 38 patients (33%) had a clinical complete response with less than 12 months of follow-up, 44 (38%) had a near-complete response, and of 15 patients who had surgery after dostarlimab alone, 12 had a pathological complete response. Medscape reported on October 19 that no disease recurrences were seen among responders after a median follow-up of more than two years.

Safety data in the label set the boundaries of the trade. Serious adverse reactions occurred in 20% of patients. The most common reactions of any grade were fatigue (32%), rash (22%), diarrhea (18%) and pruritus (17%), and 3% of patients discontinued permanently. The label carries warnings for immune-mediated adverse reactions, infusion-related reactions, complications of stem cell transplant and embryo-fetal toxicity, noting that immune-mediated events can be severe or fatal.

The FDA said on October 19 that the application had Priority Review and Breakthrough Therapy designation, that the review finished nearly four months ahead of its goal date, and that the action was the 11th approval under the Commissioner's National Priority Voucher pilot. The review ran under Project Orbis alongside Health Canada, Israel's Ministry of Health, Swissmedic and the UK MHRA. On prevalence, the agency cited published estimates that roughly 3% of locally advanced rectal cancers are dMMR or MSI-H. GSK announced on October 19 that the biomarker is found in around 5% to 10% of rectal cancers.

Analysis

The first thing to notice is that this approval rests on a single-arm trial with no randomized control group. Every patient in AZUR-1 received dostarlimab, so the 71% figure describes what happened to people who took the drug, not a head to head comparison against chemoradiation followed by surgery. In a disease where the standard of care is long established, that is a real evidentiary gap, and the accelerated pathway is the mechanism the FDA uses to bridge it later.

The second thing is the measurement problem. A 68% cCR12 by investigator assessment and a 47% cCR12 by independent central review describe the same trial, yet they differ by 21 percentage points. Central review is the more conservative and, for regulatory purposes, the more defensible number. Some of the spread is timing: 38 patients had a clinical complete response but had been followed for less than 12 months, and responses can deepen over time. Still, the gap is a reminder that organ preservation depends entirely on the quality of the endoscopy, MRI and biopsy that decide whether a tumor is really gone.

What this really means is that the endpoint of this approval is not survival but the avoidance of three treatments and the organ damage they cause. That is a legitimate and patient-centered goal, and the surveillance protocol attached to it is the price of admission. The earlier Memorial Sloan Kettering Cancer Center study (NCT04165772) in 50 patients went further: no patient received chemoradiation or rectal surgery, cCR12 was 93% and the objective response rate was 100%, and among 27 patients followed at least three years, one had a local recurrence treated with lymphadenectomy. That single recurrence is both reassuring and cautionary.

The bigger picture here is that the drug is not the bottleneck; testing and surveillance are. A biomarker present in roughly 3% of locally advanced rectal cancers, or 5% to 10% of rectal cancers by GSK's count, can only direct therapy if tumors are tested at diagnosis. Every eligible patient who is never tested receives the old sequence by default, and every patient who chooses non-operative management depends on follow-up that many centers are not set up to deliver.

Why It Matters

For patients, the practical shift is substantial. Rectal cancer surgery often means a temporary or permanent ostomy and a measurable change in quality of life, and radiation brings its own late effects. A pathway in which most trial patients finished with six months of intravenous therapy and no operation is a genuine alternative for a defined group, not a marginal tweak to an existing regimen.

For the health system, the approval creates a new dependency on non-operative management. Patients who decline surgery are not finished with care; they enter years of surveillance, and the credibility of the whole approach rests on catching the minority whose disease returns. That requires endoscopists, radiologists and oncologists working to a shared protocol, and that capacity is unevenly distributed.

For GSK, the decision adds a third approved use to a drug already cleared in endometrial cancer and in dMMR recurrent or advanced solid tumors, and it arrives with a first and only claim in this setting. It also arrives with conditions attached, since continued approval may depend on confirmatory trial results.

Next Up

Full interim AZUR-1 data are due to be presented at the ESMO Congress in October 2026, which should give the oncology community a clearer look at durability, at the central review numbers as they mature, and at what happens to the 38 patients whose responses were still short of the 12 month mark.

The supplement is also under Project Orbis review in other countries, so decisions from Health Canada, Swissmedic, the UK MHRA and Israel's Ministry of Health are the next regulatory milestones to watch. The confirmatory program is the longer test: accelerated approval is a promise to keep gathering evidence, and the recurrence-free follow-up of these 154 patients will decide whether avoiding surgery becomes a standard option or remains an experiment.